Checkpoint Blockade in Lymphoma

Article Tools REVIEW ARTICLES Immunotherapy for Hematologic Malignancies Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01522 Journal of Clinical Oncology - published online before print January 12, 2021 PMID: 33434074 Checkpoint Blockade in Lymphoma Stephen M. Ansell , MD, PhD1xStephen M. AnsellSearch for articles by this author Show More 1Division of Hematology, Mayo Clinic, Rochester, MN https://doi.org/10.1200/JCO.20.01522 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveLymphomas typically have an antitumor immune response that is ineffective because of immune suppression or exhaustion. This review discusses the deficiencies in the antitumor immune response in lymphoma and the role of immune checkpoint blockade in addressing the immune dysfunction.Knowledge GeneratedImmune checkpoint ligands are commonly overexpressed in the tumor microenvironment in lymphomas, and immune checkpoint blockade has been explored as treatment for these diseases. Although immune checkpoint blockade has been highly successful in treating patients with Hodgkin lymphoma, the results in other subtypes of lymphomas have been far less encouraging.RelevanceImmune checkpoint blockade is an effective therapy in Hodgkin lymphoma, but to improve upon the results and to increase the efficacy in other lymphomas, future treatment strategies using immune checkpoint blockade will need to use combinations with other immune active agents or with chemotherapy to optimize the antitumor immune response.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTCheckpoint Blockade in LymphomaThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Stephen M. AnsellHonoraria: WebMD, Research to PracticeResearch Funding: Bristol Myers Squibb (Inst), Seattle Genetics (Inst), Affimed Therapeutics (Inst), Regeneron (Inst), Pfizer (Inst), Trillium Therapeutics (Inst), AI Therapeutics (Inst), Celldex (Inst), Regeneron (Inst), ADC Therapeutics (Inst)No other potential conflicts of interest were reported.